CBIO — Crescent Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $195.75m
- $66.48m
- 29
- 27
- 22
- 14
Annual cashflow statement for Crescent Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51 | -63.4 | -46.7 | -36.9 | -37.9 |
| Depreciation | |||||
| Non-Cash Items | 7.58 | 6.84 | 4.69 | 4.43 | 5.59 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 3.93 | -1.17 | -4.66 | -2.56 | 1.16 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -39.2 | -57.5 | -46.5 | -34.9 | -31.1 |
| Capital Expenditures | -0.069 | -0.015 | -0.084 | -0.021 | -0.01 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | 0.03 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | -0.069 | -0.015 | -0.084 | -0.021 | 0.02 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 18.1 | 10.7 | 4.16 | 28.8 | 0.005 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -21.2 | -46.8 | -42.4 | -6.08 | -31.1 |